核苷和核苷酸类药物抗HBV疗效的影响因素研究进展

王丽丽; 梁跃东

doi:10.3969/j.issn.1001-5256.2017.07.032

核苷和核苷酸类药物抗HBV疗效的影响因素研究进展

DOI: 10.3969/j.issn.1001-5256.2017.07.032

贵州医科大学

基金项目:

贵州省科技技术基金(黔科合J字[2013]2014号)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 509
- HTML全文浏览量: 64
- PDF下载量: 170
- 被引次数: 0
出版历程
- 收稿日期: 2016-12-14
- 出版日期: 2017-07-20

Research advances in influencing factors for the antiviral effect of nucleos (t) ide analogues

Guizhou Medical University

Research funding:

摘要

摘要: 核苷和核苷酸类药物(NAs)作为一线抗病毒药物在临床上广泛使用。近年来大量的临床观察发现一些患者难以达到满意的治疗终点。介绍了慢性乙型肝炎的抗病毒指征及随访,主要总结了基线特征、HBV基因型、HBV突变耐药、患者服药依从性、是否合并其他疾病或病毒感染、血清维生素D水平几个方面对NAs抗病毒疗效的影响,表明把握恰当的抗病毒时机,治疗前对患者进行相关知识教育,治疗过程中定期随访,及时发现合并症及耐药情况有助于提高NAs的抗病毒疗效,延缓肝病的发展进程。
- 肝炎病毒,乙型 /
- 核苷类 /
- 核苷酸类 /
- 综述
Abstract: Nucleos (t) ide analogues (NAs) have been widely used in clinical practice as first-line antiviral drugs.In recent years, many clinical studies have found that some patients cannot reach a satisfactory therapeutic outcome.This article introduces the antiviral indications and follow-up of chronic hepatitis B and summarizes the influence of baseline characteristics, HBV genotype, HBV mutation and drug resistance, patients' medication compliance, presence or absence of other diseases or viral infection, and serum vitamin D level on the antiviral effect of NAs.It is pointed out that appropriate timing for antiviral therapy, patient education before treatment, regular follow-up during treatment, and timely identification of comorbidities and drug resistance help to improve the antiviral effect of NAs and delay the progression of liver diseases.
- hepatatiis B virus /
- nucleosides /
- nucleotides /
- review

HTML全文

参考文献(42)

[1]TRAN TT, TRINH TN, ABE K.New complex recombinant genotype of hepatitis B virus identified in vietnam[J].J Virol, 2008, 82 (11) :5657-5663.

[2]European Association for the Study of the Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol, 2012, 57 (1) :167-185.

[3]CAVIGLIA GP, ABATE ML, PELLICANO R, et al.Chronic hepatitis B therapy:available drugs and treatment guidelines[J].Minerva Gastroenterol Dietol, 2015, 61 (2) :61-70.

[4]VALLET-PICHARD A, POL S.Hepatitis B virus treatment beyond the guidelines:special populations and consideration of treatment withdrawal[J].Therap Adv Gastroenterol, 2014, 7 (4) :148-155.

[5]World Health Organization.Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection[R].Geneva:WHO, 2015.

[6]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].Chin JHepatol, 2011, 19 (1) :13-24. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 19 (1) :13-24.

[7]TANG CM, YAU TO, YU J.Management of chronic hepatitis B infection:current treatment guidelines, challenges, and new developments[J].World J Gastroenterol, 2014, 20 (20) :6262-6278.

[8]Chinese Society of Hepatology, Chinese Society of Infectious Diseases.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[9]YU LF, LIANG WF, ZHANG SP, et al.Baseline HBs Ag and ALTlevels are important forecasting factors of HBe Ag seroconversion in HBe Ag positive chronic hepatitis B treated with telvivudine[J].Chin J Microecol, 2014, 26 (2) :184-187. (in Chinese) 俞立飞, 梁伟峰, 章松平, 等.基线HBs Ag和ALT水平是替比夫定治疗HBe Ag阳性慢性乙型肝炎患者e抗原血清学转换的重要预测因素[J].中国微生态学杂志, 2014, 26 (2) :184-187.

[10]LI X, WANG Y, HAN D, et al.Correlation of hepatitis B surface antigen level with response to telbivudine in naive patients with chronic hepatitis B[J].Hepatol Res, 2014, 44 (2) :187-193.

[11]TSAI MC, LEE CM, CHIU KW, et al.A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice[J].J Antimicrob Chemother, 2012, 67 (3) :696-699.

[12]ZHU XF, LU LX, WANG Y, et al.Effect and predictive elements for 52 weeks telbivudine treatment on native HBe Ag positive chronic Hepatitis B[J].Hepat Mon, 2011, 11 (12) :980-985.

[13]LIU CH, KAO JH.Global perspective on the natural history o chronic hepatitis B:role of hepatitis B virus genotypes A to J[J].Semin Liver Dis, 2013, 33 (2) :97-102.

[14]XIAN YC, CHENG SQ.Advances in hepatitis B virus genotyping and application[J].Int J Virol, 2016, 23 (4) :285-288. (in Chinese) 冼永超, 程书权.乙肝病毒基因分型研究及应用进展[J].国际病毒学杂志, 2016, 23 (4) :285-288.

[15]YANG LM, PENG X, ZHAO YR, et al.Relationship of HBV genotypes to changes of liver biopsies and to respinses to antiviral therapy of nucleoside analogs[J].J Pract Hepatol, 2012, 15 (2) :120-122. (in Chinese) 杨丽敏, 彭勋, 赵艳茹, 等.不同HBV基因型感染慢性乙型肝炎患者对核苷酸类药物治疗的应答反应比较[J].实用肝脏病杂志, 2012, 15 (2) :120-122.

[16]YANG JH, Ch EN HB, ZANG H, et al.HBV genotype C strains with spontaneous YMDD mutations may be a risk factor for hepatocellular carcinoma[J].J Med Virol, 2014, 86 (6) :913-917.

[17]HUANG ZM, HUANG QW, QIN YQ, et al.Clinical characteristics and distribution of hepatitis B virus genotypes in Guangxi Zhuang population[J].World J Gastroenterol, 2005, 11 (41) :6525-6529.

[18]KONG LH, GAO SX, KE YX.Clinical application of DNA sequencing for detecting point mutations in hepatitis B virus associated with drug resistance[J].J South Med Univ, 2012, 32 (2) :277-279. (in Chinese) 孔令和, 高素香, 柯云霞.PCR产物直接测序检测乙型肝炎病毒耐药变异位点[J].南方医科大学学报, 2012, 32 (2) :277-279.

[19]CHENG J.The past, present and future of the treatment of chronic hepatitis B[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition, 2015, 9 (1) :1-3. (in Chinese) 成军.慢性乙型肝炎治疗的过去、现在和未来[J/CD].中华实验和临床感染病杂志:电子版, 2015, 9 (1) :1-3.

[20]WESTLAND CE, YANG H, DELANEY WE, et al.Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients[J].J Viral Hepat, 2005, 12 (1) :67-73.

[21]YANG S, XING H, WANG Q, et al.De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine[J].Ann Clin Microbiol Antimicrob, 2016, 15:24.

[22]HAN SH, JING W, MENA E, et al.Adherence, persistence, healthcare utilization, and cost benefits of guideline-recommended hepatitis B pharmacotherapy[J].J Med Econ, 2012, 15 (6) :1159-1166.

[23]WANG HY.Effect of nursing intervention on treatment compliance of anti-virus therapy and quality of life in patients with chronic hepatitis B[J].Nurs Integr Tradit Chin West Med, 2015, 3 (1) :76-77. (in Chinese) 汪海燕.护理干预对慢性乙肝患者抗病毒治疗依从性及生活质量的影响[J].中西医结合护理, 2015, 3 (1) :76-77.

[24]ZHANG XN, ZHANG Z, CAO SY, et al.Meta-analysis on the effect of health education on treatment compliance based for hepatitis B patients in China[J].Jiangsu J Prevent Med, 2012, 23 (1) :6-9. (in Chinese) 张学宁, 张珍, 曹松玉, 等.我国乙肝患者遵医行为教育干预效果的Meta分析[J].江苏预防医学, 2012, 23 (1) :6-9.

[25]SUNDUS A, SIDDIQUE O, IBRAHIM MF, et al.Hepatitis patients lost to follow-up at a liver centre in a tertiary care hospital of Karachi, Pakistan---a cross-sectional descriptive study[J].JPak Med Assoc, 2013, 63 (12) :1566-1570.

[26]WEI Y.The effect of cognitive nursing on the treatment compliance and quality of life of patients with chronic hepatitis B[J].Int J Nurs, 2014, 33 (3) :504-506. (in Chinese) 魏懿.认知护理对乙肝患者治疗依从性及生活质量的影响[J].国际护理学杂志, 2014, 33 (3) :504-506.

[27] ZHANG DF.Understanding immunopathogenic processes of the hepatitis B virus provides insights into potential novel targets for antivtral therapy[J].Chin J Hepatol, 2012, 20 (1) :71-74. (in Chinese) 张定凤.乙型肝炎的免疫发病机制及治疗靶位的探讨[J].中华肝脏病杂志, 2012, 20 (1) :71-74.

[28]YIN JW, WANG JK, YIN GQ.New progress and opinions of the immunological response for HBV infection[J/CD].Chin J Liver Dis:Electronic Edition, 2016, 8 (3) :34-37. (in Chinese) 殷稼雯, 王进科, 殷国庆.HBV感染免疫学应答的新进展和新观点[J/CD].中国肝脏病杂志:电子版, 2016, 8 (3) :34-37.

[29]SHA XY, ZHAO YR.Influence of cellular immune function on antiviral response in patients with chronic hepatitis B[J].Shanxi Med J, 2014, 8 (43) :1082-1083. (in Chinese) 沙晓莹, 赵英仁.慢性乙型肝炎患者细胞免疫功能对抗病毒疗效的影响[J].陕西医学杂志, 2014, 8 (43) :1082-1083.

[30]LI Y, WANG X, CHENG LW, et al.Effects of serum levels of chemokines on sustained virological response in patients with HBe Ag-positive chronic hepatitis B after treatment with pegylated interferonα-2b[J].J Clin Hepatol, 2016, 32 (3) :456-471. (in Chinese) 李彦, 王霞, 成立伟, 等.血清趋化因子对HBe Ag阳性慢性乙型肝炎患者经聚乙二醇干扰素α治疗后持续病毒学应答的影响[J].临床肝胆病杂志, 2016, 32 (3) :456-471.

[31]PUBLICOVER J, GAGGAR A, NISHIMURA S, et al.Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B[J].J Clin Invest, 2013, 123 (9) :3728-3739.

[32]AKBAR SM, AL-MAHTAB M, KHAN MS, et al.Immune therapy for hepatitis B[J].Ann Transl Med, 2016, 4 (18) :335.

[33]WU X, JIA J, YOU H.Thymosin alpha-1 treatment in chronic hepatitis B[J].Expert Opin Biol Ther, 2015, Suppl 1:s129-s132.

[34]XU B, SHAO W.Influence of chronic hepatitis B combined with depression on antiviral effect of lamivudine[J].Chin J Med, 2009, 44 (3) :32-33. (in Chinese) 涂波, 邵薇.慢性乙肝合并抑郁对拉米夫定抗病毒疗效的影响[J].中国医刊, 2009, 44 (3) :32-33.

[35]WANG YL, ZHANG B, LI BQ, et al.Antiviral efficacy of adefovir ester on fatty liver of HBe Ag positive patients with chronic hepatitis B[J].J Pract Med, 2015, 7 (31) :1079-1081. (in Chinese) 王艳玲, 张冰, 李炳庆, 等.脂肪肝对HBe Ag阳性慢性乙型肝炎患者应用阿德福韦酯抗病毒疗效的影响[J].实用医学杂志, 2015, 7 (31) :1079-1081.

[36]JIN X, CHEN YP, YANG YD, et al.Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B[J].PLo S One, 2012, 7 (3) :e34198.

[37]WANG YQ, ZHOU ZZ, LI T, et al.Significance of the Antinuclear Antibody (ANA) and antoimmune liver disease antibody for patients with hepatitis B[J].J Mod Lab Med, 2014, 1 (29) :141-146. (in Chinese) 汪永强, 周振忠, 李婷, 等.抗核抗体与免疫性肝病抗体对乙型肝炎患者预后与转归的意义[J].现代检验医学杂志, 2014, 1 (29) :141-146.

[38]WANG C, JI D, CHEN J, et al.Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis Ctreated with direct-acting antiviral agents[J].Clin Gastroenterol Hepatol, 2017, 15 (1) :132-136.

[39]HAYASHI K, ISHIGAMI M, ISHIZU Y, et al.A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy:hepatitis B virus reactivation or acute self-limited hepatitis?[J].Clin J Gastroenterol, 2016, 9 (4) :252-256.

[40]LAN B, CHEN LE, SUN YH, et al.Research advances in the association between vitamin D and liver disease[J].J Hubei Univ Med, 2013, 32 (4) :359-362.兰斌, 陈立娥, 孙毓徽, 等.维生素D与肝病相关性研究进展[J].湖北医药学院学报, 2013, 32 (4) :359-362.

[41]HOAN NX, KHUYEN N, BINH MT, et al.Association of vitamin D deficiency with hepatitis B virus-related liver diseases[J].BMC Infect Dis, 2016, 16 (1) :507-514.

[42]MAHMUD M, NSEIR W, ABU ELLIGA O, et al.Normal vitermin D levels are associated with spontaneous hepatitis B surface antigen seroclearance[J].World J Hepatol, 2013, 5 (6) :328-331.

施引文献

资源附件(0)

访问统计